Howard Herrmann
Latest contributions
TAVI - Head-to-head comparative studies
22 May 2025 – From EuroPCR 2025
Compare head-to-head outcomes of various TAVI devices through real-world registries and meta-analyses. This session provides insights into performance differences between self-expanding and balloon-expandable valves to inform clinical decision-making.
Hotline TAVI 2: outcomes with new and established devices
21 May 2025 – From EuroPCR 2025
Review outcomes of new and established TAVI devices through pooled analyses and multicenter studies. Topics include comparisons of balloon-expandable valves, intra- versus supra-annular self-expanding valves, and insights from the ACURATE IDE and ACURATE prime studies.
Hotline - ACURATE neo2 under-expansion in the ACURATE IDE study: a post-hoc analysis
21 May 2025 – From EuroPCR 2025
Howard Herrmann and Raj Makkar discuss a sub-study of the ACURATE IDE trial, which examined valve under-expansion detected by fluoroscopy. Among 1,500 patients with aortic stenosis, 22 % of ACURATE neo2 valves showed under-expansion, often linked to heavy valve calcification.
Patients with under-expanded valves faced higher risks...
TAVI Hotline: new devices, new approaches
15 May 2024 – From EuroPCR 2024
Innovation and strategies in TAVI: design, data and directions for clinical practice
15 May 2024 – From EuroPCR 2024
Watch this session to explore considerations for TAVI implantation in small annuli, gain insights into future lifetime management, learn about the benefits of FX technology and clinical evidence beyond small annuli, and witness a live case procedure showcasing the innovation of FX plus. This session is...
Self-expanding versus balloon-expandable transcatheter aortic valve replacement in patients with small aortic annuli: Primary outcomes from the randomized SMART Trial
07 Apr 2024
Alessandro Sticchi interviews Howard C. Herrmann about the primary outcomes from the randomized SMART Trial which he presented at ACC.24 in Atlanta.
Patients with severe aortic stenosis and small aortic annuli, typically female and often underrepresented in clinical trials, are at risk for impaired valvular hemodynamics and associated...
Author
Author
Long-term valve performance for the next decade and beyond
17 May 2023 – From EuroPCR 2023
How can TAVI outcomes be made better for younger patients with longer life horizons? Check-out in this session where you also will be able to gain in the understanding of the structural challenges of providing TAVI services and see how innovation can contribute to optimal outcomes and...
Which valve for which patient? - Part 1: simple anatomy
17 May 2023 – From EuroPCR 2023
Explore this session to gain insights into the influence of valve design on hemodynamic performance and durability, understand its implications for risk factors associated with TAVI in bicuspid aortic valves, and grasp the relationship between valve design, implantation techniques, and the emergence of new conduction abnormalities...
TAVI in patients with long-life expectancy - LIVE case
16 May 2023 – From EuroPCR 2023
Watch the case of a 75-year-old male patient with history of TIA, symptomatic severe aortic stenosis with RBBB, and preserved LV function. The heart team's decision was to perform TAVI with PCI on LAD a few days before procedure.
First, a cerebral protection device (Sentinel) was implanted....
